100 related articles for article (PubMed ID: 18694811)
1. Stability and bioactivity of nanocomplex of TNF-related apoptosis-inducing ligand.
Na SJ; Chae SY; Lee S; Park K; Kim K; Park JH; Kwon IC; Jeong SY; Lee KC
Int J Pharm; 2008 Nov; 363(1-2):149-54. PubMed ID: 18694811
[TBL] [Abstract][Full Text] [Related]
2. Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis.
Kim YJ; Chae SY; Jin CH; Sivasubramanian M; Son S; Choi KY; Jo DG; Kim K; Chan Kwon I; Lee KC; Park JH
Biomaterials; 2010 Dec; 31(34):9057-64. PubMed ID: 20813405
[TBL] [Abstract][Full Text] [Related]
3. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles.
Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY
Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763
[TBL] [Abstract][Full Text] [Related]
4. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity.
Kim TH; Jiang HH; Park CW; Youn YS; Lee S; Chen X; Lee KC
J Control Release; 2011 Feb; 150(1):63-9. PubMed ID: 21062635
[TBL] [Abstract][Full Text] [Related]
5. A sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-co-glycolic acid) (PLGA) microspheres.
Kim H; Jeong D; Kang HE; Lee KC; Na K
J Pharm Pharmacol; 2013 Jan; 65(1):11-21. PubMed ID: 23215683
[TBL] [Abstract][Full Text] [Related]
6. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles.
Lim SM; Kim TH; Jiang HH; Park CW; Lee S; Chen X; Lee KC
Biomaterials; 2011 May; 32(13):3538-46. PubMed ID: 21306770
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of HA-PEG-PCL intelligent core-corona nanoparticles for delivery of doxorubicin.
Yadav AK; Mishra P; Jain S; Mishra P; Mishra AK; Agrawal GP
J Drug Target; 2008 Jul; 16(6):464-78. PubMed ID: 18604659
[TBL] [Abstract][Full Text] [Related]
8. Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution.
Kim TH; Jiang HH; Youn YS; Park CW; Lim SM; Jin CH; Tak KK; Lee HS; Lee KC
J Pharm Sci; 2011 Feb; 100(2):482-91. PubMed ID: 20669330
[TBL] [Abstract][Full Text] [Related]
9. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
10. Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Youn YS; Shin MJ; Chae SY; Jin CH; Kim TH; Lee KC
Biotechnol Lett; 2007 May; 29(5):713-21. PubMed ID: 17318333
[TBL] [Abstract][Full Text] [Related]
11. Human serum albumin-TRAIL conjugate for the treatment of rheumatoid arthritis.
Byeon HJ; Min SY; Kim I; Lee ES; Oh KT; Shin BS; Lee KC; Youn YS
Bioconjug Chem; 2014 Dec; 25(12):2212-21. PubMed ID: 25387356
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors.
Reis CR; van der Sloot AM; Szegezdi E; Natoni A; Tur V; Cool RH; Samali A; Serrano L; Quax WJ
Biochemistry; 2009 Mar; 48(10):2180-91. PubMed ID: 19236007
[TBL] [Abstract][Full Text] [Related]
13. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
Wang S
Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
[TBL] [Abstract][Full Text] [Related]
14. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
Zauli G; Rimondi E; Celeghini C; Milani D; Secchiero P
J Cell Physiol; 2010 Feb; 222(2):357-64. PubMed ID: 19877156
[TBL] [Abstract][Full Text] [Related]
16. The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases.
Audo R; Combe B; Coulet B; Morel J; Hahne M
Cell Death Differ; 2009 Sep; 16(9):1227-37. PubMed ID: 19407827
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers.
He M; Zhao Z; Yin L; Tang C; Yin C
Int J Pharm; 2009 May; 373(1-2):165-73. PubMed ID: 19429302
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
Frese S; Schüller A; Frese-Schaper M; Gugger M; Schmid RA
Anticancer Res; 2009 Aug; 29(8):2905-11. PubMed ID: 19661294
[TBL] [Abstract][Full Text] [Related]
19. Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.
Taniguchi H; Yoshida T; Horinaka M; Yasuda T; Goda AE; Konishi M; Wakada M; Kataoka K; Yoshikawa T; Sakai T
Cancer Res; 2008 Nov; 68(21):8918-27. PubMed ID: 18974136
[TBL] [Abstract][Full Text] [Related]
20. Multiple hyperthermia-mediated release of TRAIL/SPION nanocomplex from thermosensitive polymeric hydrogels for combination cancer therapy.
Zhang ZQ; Song SC
Biomaterials; 2017 Jul; 132():16-27. PubMed ID: 28399459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]